Senaste försöken

EudraCT Number: 2007-002586-12

Sponsor Protocol Number: 1160.63

Start Date:

Sponsor Name: Boehringer Ingelheim Pharma GmbH & Co. KG

Full Title: Twice-daily oral direct thrombin inhibitor dabigatran in the long-term prevention of recurrent symptomatic venous thromboembolism in patients with symptomatic deep-vein thrombosis or pulmonary embo...

Medical condition: long-term prevention of recurrent symptomatic venous thromboembolism (VTE) in patients with symptomatic deep-vein thrombosis (DVT) or pulmonary embolism (PE) who completed 6 to 18 months of treatme...

Disease:	Version	SOC Term	Classification Code	Term	Level
	9.1		10049909	Venous thromboembolism prophylaxis	LLT

Population Age: Adults, Elderly

Gender: Male, Female

Trial protocol: DE (Completed) SE (Completed) AT (Completed) IT (Completed) PL (Completed) CZ (Completed) NL (Completed) BE (Completed) LT (Completed) LV (Completed) EE (Completed)

Trial results: View results

EudraCT Number: 2007-005865-37

Sponsor Protocol Number: PIL-629-WEB-0128-I

Start Date:

Sponsor Name: Medizinische Fakultät der Technischen Universität München, Vertreten durch den Dekan

Full Title: Levofloxacin vs Piperacillin/Sulbactam and Sultamicillin in patients with acute cholecystitis. A double blind, randomized study.

Medical condition: acute cholecystitis

Disease:

Version

SOC Term

Classification Code

Term

Level

Population Age: Adults, Elderly

Gender: Male, Female

Trial protocol: DE (Prematurely Ended)

Trial results: View results

EudraCT Number: 2017-004554-42

Sponsor Protocol Number: TAMDMD

Start Date:

Sponsor Name: University of Basel Children's Hospital, Division of Neuropediatrics

Full Title: Tamoxifen in Duchenne muscular dystrophy: A multicenter, randomised, double-blind, placebo-controlled, phase 3 safety and efficacy 48-week trial Tamoxifen in Duchenne muscular dystrophy: A 48-week...

Medical condition: Duchenne muscular dystrophy

Disease:	Version	SOC Term	Classification Code	Term	Level
	20.0	10010331 - Congenital, familial and genetic disorders	10013801	Duchenne muscular dystrophy	PT

Population Age: Children, Adolescents, Under 18

Gender: Male

Trial protocol: DE (Ongoing) GB (GB - no longer in EU/EEA) FR (Ongoing) ES (Ongoing) NL (Ongoing) BE (Ongoing)

Trial results: (No results available)

EudraCT Number: 2016-001767-37

Sponsor Protocol Number: 178-CL-204

Start Date:

Sponsor Name: Astellas Pharma Global Development Inc.

Full Title: A Phase 3, Double blind, Randomized, Multicenter, Parallel Group, Placebo controlled Sequential Dose Titration Study to Evaluate Efficacy, Safety and Pharmacokinetics of Mirabegron in Pediatric Sub...

Medical condition: Overactive bladder (OAB)

Disease:	Version	SOC Term	Classification Code	Term	Level
	23.1	100000004857	10059617	Overactive bladder	LLT

Population Age: Children, Adolescents, Under 18

Gender: Male, Female

Trial protocol: DE (Completed) NL (Completed) BE (Completed) NO (Completed) FR (Completed) DK (Completed) PL (Completed) IT (Completed) ES (Ongoing)

Trial results: View results

EudraCT Number: 2016-004786-80

Sponsor Protocol Number: ANAKIN

Start Date:

Sponsor Name: Ruprecht-Karls-University Heidelberg, Medical Faculty

Full Title: A phase IIa, randomized, placebo-controlled, double-blind, cross-over study to evaluate safety and efficacy of subcutanous administration of anakinra in patients with cystic fibrosis.

Medical condition: Cystic fibrosis

Disease:	Version	SOC Term	Classification Code	Term	Level
	20.0	100000004850	10028141	Mucoviscidosis	LLT

Population Age: Adolescents, Under 18, Adults

Gender: Male, Female

Trial protocol: DE (Ongoing)

Trial results: (No results available)

EudraCT Number: 2016-004479-35

Sponsor Protocol Number: VX16-661-115

Start Date:

Sponsor Name: Vertex Pharmaceuticals Incorporated

Full Title: A Phase 3, Double-blind, Parallel-group Study to Evaluate the Efficacy and Safety of Tezacaftor in Combination With Ivacaftor in Subjects Aged 6 Through 11 Years With Cystic Fibrosis, Homozygous or...

Medical condition: Cystic Fibrosis

Disease:	Version	SOC Term	Classification Code	Term	Level
	20.0	10010331 - Congenital, familial and genetic disorders	10011762	Cystic fibrosis	PT

Population Age: Children, Under 18

Gender: Male, Female

Trial protocol: IE (Completed) DK (Completed) BE (Completed) DE (Completed) GB (Completed) PL (Completed) FR (Completed)

Trial results: View results

EudraCT Number: 2015-004139-11

Sponsor Protocol Number: VAC52150EBL4001

Start Date:

Sponsor Name: Janssen Vaccines & Prevention B.V.

Full Title: A Multicountry, Prospective, Clinical Safety Study of Subjects Exposed to the Candidate Ebola Vaccines Ad26.ZEBOV and/or MVA-BN-Filo

Medical condition: Ebola

Disease:	Version	SOC Term	Classification Code	Term	Level
	20.0	10021881 - Infections and infestations	10014071	Ebola disease	PT

Population Age: Infants and toddlers, Children, Adolescents, Under 18, Adults, Elderly

Gender: Male, Female

Trial protocol: GB (GB - no longer in EU/EEA) FR (Completed)

Trial results: (No results available)

EudraCT Number: 2006-002847-96

Sponsor Protocol Number: DRI6012

Start Date:

Sponsor Name: Sanofi aventis US Inc.

Full Title: A 13-week Multinational, Randomized, Double-Blind, Placebo-Controlled, Dose-Response Trial Assessing the Safety, Tolerability and Efficacy of AVE0010 in Metformin-Treated Subjects with Type 2 Diabe...

Medical condition: The current study is designed to confirm the already observed clinically meaningful pharmacodynamic effect of AVE0010 on glycemic control, as measured by HbA1c, and to determine the clinically rele...

Disease:	Version	SOC Term	Classification Code	Term	Level
	8.1		10012613	Diabetes mellitus non-insulin-dependent	LLT

Population Age: Adults, Elderly

Gender: Male, Female

Trial protocol: BG (Prematurely Ended)

Trial results: View results

EudraCT Number: 2014-002710-23

Sponsor Protocol Number: P140203

Start Date:

Sponsor Name: ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS (AP-HP)

Full Title:

Medical condition:

Disease:	Version	SOC Term	Classification Code	Term	Level
	18.0	10010331 - Congenital, familial and genetic disorders	10054935	Aicardi's syndrome	PT

Population Age: Infants and toddlers, Children, Adolescents, Under 18

Gender: Male, Female

Trial protocol: FR (Completed)

Trial results: (No results available)

EudraCT Number: 2019-004190-46

Sponsor Protocol Number: D5136C00013

Start Date:

Sponsor Name: AstraZeneca AB

Full Title: A Randomised, Double-Blind, Parallel-Group, Multicentre, Phase III Study to Evaluate the Effect of Ticagrelor versus Placebo in Reducing the Number of Vaso-Occlusive Crises in Paediatric Patients A...

Medical condition: Sickle Cell Disease

Disease:	Version	SOC Term	Classification Code	Term	Level
	21.0	100000004850	10040645	Sickle cell disease NOS	LLT

Population Age: Infants and toddlers, Children, Adolescents, Under 18

Gender: Male, Female

Trial protocol: GB (Prematurely Ended)

Trial results: (No results available)

Senaste försöken

Sponsorer och medarbetare

Medicinska tillstånd

Läkemedelsinterventioner